Diabetic nephropathy is associated with cardiovascular morbidity and mortality [1, 2] . It is also associated with increased concentrations of serum total and LDL-cholesterol, triglyceride and apolipoprotein (apo)B [3, 4, 5, 6] . In macroalbuminuria HDL-cholesterol is reduced but in microalbuminuric patients HDL-cholesterol has been reported to be reduced [3, 4] , unchanged [7, 8] Abstract Aims/hypothesis. To examine whether the HDL-cholesterol:apoA-I + apoA-II ratio and the e2 allele are related to albuminuria at baseline and whether they are risk factors for progression of albuminuria in a cohort study of patients with Type I (insulin-dependent) diabetes mellitus. Methods. At baseline, the study cohort comprised 617 patients, aged 15±60 years, from seven European diabetic centres of the EURODIAB study. Albumin excretion rate, measured in a central laboratory, was categorised as normoalbuminuria at 20 mg/min or less, microalbuminuria between 20 and 200 mg/min or macroalbuminuria at 200 mg/min or over. Of the 250 patients who were normoalbuminuric at baseline and had follow-up albuminuria measurements, 34 patients were defined as early progressors. Results. At baseline, the mean HDL-cholesterol:apoA-I + apoA-II ratio was lower in macroalbuminuric patients (0.79, 95 % CI:0.74±0.83) compared with normoalbuminuric (0.88, 95 % CI:0.87±0.90) patients (p = 0.0002, adjusted for age and sex). At follow-up, 34 patients who progressed from normoalbuminuria to microalbuminuria or macroalbuminuria also had a slightly lower baseline ratio (0.85, 95 % CI:0.80±0.89) than those 216 who remained normoalbuminuric (0.89, 95 % CI:0.87±0.92) (adjusted p = 0.08). Neither of these relations were independent of LDL-cholesterol or fasting triglyceride. There was no association of the e2 allele with albuminuria either at baseline (OR = 1.4, 95 % CI:0.7±2.8) or with progression of albuminuria (OR = 0.4, 95 % CI:0.1±3.5). Conclusion/interpretation. There is an inverse relation of HDL-cholesterol:apoA-I + apoA-II ratio with albuminuria at baseline. This lower ratio in microalbuminuric or macroalbuminuric patients could contribute to the increased risk of cardiovascular disease associated with nephropathy. There is weak evidence that HDL-composition is a risk factor for progression of albuminuria and no association of the e2 allele with diabetic nephropathy. [Diabetologia 2000 
An important question is whether there are also abnormalities of lipoprotein composition which contribute to the risk of diabetic nephropathy. Apolipoprotein A-I and apolipoprotein A-II make up over 85 % of the protein found in HDL. The measurement of these apolipoproteins in plasma in conjunction with HDL-cholesterol provides a surrogate assessment of HDL composition [10] . In one previous study the HDL-cholesterol:apoA-I + apoA-II ratio was statistically significantly lower in those with microalbuminuria and macroalbuminuria compared with normoalbuminuric patients with Type I (insulin-dependent) diabetes mellitus [11] . We have examined whether albuminuria is associated with derangement of HDL-cholesterol:apoA-I + apoA-II ratio at baseline in a cohort of 617 Type I diabetic patients.
In addition to lipid abnormalities arising secondary to nephropathy there is also some evidence to suggest that lipid abnormalities are important in the initiation and progression of nephropathy [5] . Triglyceride-rich lipoproteins have been associated with diabetic nephropathy [3, 4, 7, 8] . There are no previous studies examining whether HDL-cholesterol:apoA-I + apoA-II ratio is prospectively associated with nephropathy. We therefore examined this question in 250 Type I diabetic patients of the original cohort of 617 patients who were normoalbuminuric at baseline and had follow-up albuminuria data available.
There is evidence that diabetic nephropathy is partly genetically determined [12] . Given the data suggesting a role for lipids in nephropathy progression, genes involved in lipoprotein metabolism are candidates for nephropathy. Apolipoprotein E is a component of triglyceride-rich lipoproteins, chylomicrons, very low-density lipoproteins and their remnants. It is also found to a lesser extent in high-density lipoproteins [13, 14] . The gene for apoE, located on chromosome 19, has three common alleles, e2, e3, and e4, which code for three major isoforms, resulting in six common genotypes [13, 14] . The presence of the e2 allele results in an accumulation of remnants of triglyceride-rich lipoprotein particles and a decrease in plasma LDL concentration [14] . Because the e2 allele is associated with an increased concentration of triglyceride [15, 16] it is a candidate gene for the development of nephropathy. Three small studies in Type I diabetic patients have found conflicting evidence on whether the e2 allele is a risk factor for nephropathy [17, 18, 19] . Therefore in this study we also examined whether the e2 allele is associated with albuminuria, cross-sectionally and prospectively.
Subjects and methods
Study design and subjects. Full details of the design and recruitment in the EURODIAB IDDM Complications Study have been published elsewhere [20] . This was a cross-sectional clinic-based study, carried out in 1989±1991. It was set up to explore risk factors for diabetic complications in 3250 Type I diabetic patients who were selected at random, aged 15 to 60 years and attending 31 clinics in 16 European countries. Sampling was stratified by age, sex and diabetes duration. At each clinic, informed consent from all patients and ethics committee approval for the study were obtained. Type I diabetes was defined as diabetes diagnosed before the age of 36 years with a continuous need for insulin 1 year after diagnosis.
Study cohort. Serum samples for the analysis of apolipoproteins, were available from seven of the EURODIAB centres (n = 617), which formed the baseline cohort in this study. The sub-sample (n = 617) did not differ from the total EURODI-AB sample (n = 3250), in age, sex, duration of diabetes, albuminuria, HbA 1 c , systolic blood pressure or BMI.
Follow-up study. Approximately 6±8 years after the baseline investigations, the patients were traced and invited back for re-examination. Of the 617 patients, 426 patients were normoalbuminuric at baseline and of these 250 patients had followup albuminuria measurements, which allowed progression to be defined. Of the remaining 176 patients, 11 patients had died, 45 were ascertained to be alive but were not examined, and 120 were examined but follow-up albuminuria data were not available because of inadequate sample collection or concurrent infection. Progression from normoalbuminuria at baseline to microalbuminuria or macroalbuminuria was assessed by two 24-h urine collections (only one was done at baseline), measuring urinary albumin excretion after a mean follow-up period of 7.4 years. The term`early progressors' was used for patients who progressed from normoalbuminuria to microalbuminuria or macroalbuminuria at follow-up. The term`non-progressors' was used for patients who stayed normoalbuminuric at follow-up. Of the 250 patients who were normoalbuminuric at baseline and had follow-up albuminuria measurements, 34 were early progressors and 216 were nonprogressors. The baseline distribution of the e2 allele and the HDL composition was similar in those 250 patients compared with the total group (n = 617).
Measurements. Body Mass Index (BMI) was calculated (kg/ m 2 ). Blood pressure was measured by a random zero sphygmomanometer (Hawskley, Lancing, UK) with the patient seated. Subjects conducted a single timed 24-h urine collection for the calculation of the albumin excretion rate (AER) after excluding proteinuria due to urinary tract infection. Urinary albumin was measured centrally by an immunoturbidimetric method [21] (Sanofi Diagnostics Pasteur, Minneapolis, Minn., USA). Albumin excretion rate was categorised as normoalbuminuria at 20 mg/min or less, microalbuminuria between 20 and 200 mg/min and macroalbuminuria at 200 mg/min or more. The HbA 1c value was measured by an enzyme immunoassay using a monoclonal antibody against HbA 1 c [22] . A single venous blood sample was taken for the measurement of plasma lipids and HbA 1c . Blood was collected in EDTA tubes after an overnight fast and before the morning insulin injection. Plasma was separated by centrifugation at 1500 g for 10 min at ambient temperature. Aliquots of whole blood, plasma and urine were stored at ±20 C at each centre until transported to the central laboratory on solid carbon dioxide. On receipt, samples were kept at ±20 C until analysed [23] . The triglyceride [24] and cholesterol [25] concentration of plasma and the cholesterol concentration of HDL [26] were assayed by standard enzymatic methods (Boehringer Mannheim, Lewes, UK) using a cobas-bio centrifugal analyser (Roche, Welwyn Garden City, Herts, UK). For HDL, samples with triglyceride concentrations more than 3 mmol/l were diluted with 0.15 mol/l sodium chloride solution before chemical precipitation. Lowdensity lipoprotein cholesterol (LDL-cholesterol) was calculated from Friedewald's formula [27] . Stored serum samples were analysed for apolipoproteins (A-I and A-II) by an immunoturbidimetric method (mmol/l) with commercially available kits (Boehringer Mannheim) [28, 29] . The ratio of HDL-cholesterol and the sum of apoA-I and apoA-II was calculated (HDL-cholesterol:apoA-I + apoA-II).
Apolipoprotein E phenotype was measured using a rapid micromethod. The method is based on isoelectric focusing of either delipidated or guanide-HCL-treated serum in a horizontal slab gel system, followed by immunoblotting using either polyclonal or monoclonal anti-apolipoprotein E antibodies as the first antibody [30] . Apolipoprotein E genotype was not measured directly but derived from the measurement of apoE phenotype. The laboratory measurements were conducted in a central laboratory in Helsinki, Finland.
Statistical analyses. All analyses were done using the SAS statistical package (SAS, Cary, N. C., USA). Log transformations were used for variables with skewed distributions. Apolipoprotein E phenotypes were expressed as E3/1, E3/2, E3/3, E4/2, E4/3, E4/4. For the patients with e2 allele the E3/2 and E4/2 phenotypes were combined as one group [31] . The chi-squared test for trend was used to analyse the differences between ApoE phenotype and albuminuria. Logistic regression analysis was used for further analysis of differences between the e2 allele and albuminuria. In the final logistic model adjustment was made for age, sex, LDL-cholesterol, fasting triglyceride and HDL-cholesterol.
Analysis of covariance (ANCOVA) was used to test for associations between HDL-cholesterol:apoA-I + apoA-II ratio and albuminuria at baseline and with progression of albuminuria. These analyses were computed by fitting linear regression models for the HDL-cholesterol:ApoA-I + ApoA-II ratio and including indicator variables for the albuminuria groups. The following covariates were entered separately into the model: AER (log transformed), age, sex, duration of diabetes, HbA 1 c , BMI, systolic blood pressure, LDL-cholesterol, fasting triglyceride and smoking. A p value of less than 0.05 was considered statistically significant.
Results
Distribution of characteristics between normoalbuminuric and albuminuric patients at baseline. There was a significant difference between patients with normoalbuminuria (n = 426), microalbuminuria (n = 124) and macroalbuminuria (n = 52) for the following variables: duration of diabetes, BMI, HbA 1 c , systolic blood pressure, diastolic blood pressure, smoking, total cholesterol, LDL-cholesterol, fasting triglyceride and apoA-II. The LDL-cholesterol, fasting triglyceride and apoA-II concentrations were increased in microalbuminuric or macroalbuminuric patients compared with normoalbuminuric patients, whereas apoA-I was similar in all albuminuria groups (Table 1) .
Distribution of characteristics between early progressors and non-progressors. Duration of diabetes (p = 0.04) and HbA 1 c at baseline (p = 0.0008) were the only two variables that showed a significant difference between early progressors (n = 34) and nonprogressors (n = 216) (data not shown).
HDL-cholesterol:apoA-I + apoA-II ratio and albuminuria at baseline. The HDL-cholesterol:apoA-I + apoA-II ratio was inversely related to albuminuria at baseline, with mean values of 0.88 (95 % CI: 0.87±0.90), 0.87 (95 % CI: 0.84±0.89) and 0.79 (95 % CI: 0.74±0.83) in those with normoalbuminuria, microalbuminuria and macroalbuminuria, respectively (p = 0.0002, adjusted for age and sex) (Fig. 1) . This relation was mainly due to the lower HDL-cholesterol:apoA-I + apoA-II ratio in the macroalbuminuria group compared with the microalbuminuria and normoalbuminuria groups (p = 0.03 and p = 0.0001, respectively). Potential confounding variables, duration of diabetes, HbA 1 c , BMI, systolic blood pressure, LDL-cholesterol, fasting triglyceride and smoking, were entered in the model one by one to analyse HDL-cholesterol:apoA-I + apoA-II ratio and progression of albuminuria. Early progressors showed a slightly lower HDL-cholesterol:apoA-I + apoA-II ratio (0.85, 95 % CI: 0.80±0.89) at baseline than nonprogressors (0.89, 95 % CI: 0.87±0.92) (p = 0.08, adjusted for AER, age and sex). On adjustment for LDL-cholesterol or fasting triglyceride this difference was abolished. The mean LDL-cholesterol concentration at baseline was 3.8 mmol/l (1.0 SD) and the mean triglyceride concentration was 1.0 mmol/l (1.8 SD). There was no statistically significant difference in baseline LDL-cholesterol or fasting triglyceride between early progressors and non-progressors, the lipids were, however, highly correlated. The correlation coefficients between HDL-cholesterol:apoA-I + apoA-II ratio and triglyceride ±0.6 (p = 0.0001) and with LDL-cholesterol ±0.4 (p = 0.0001).
Apolipoprotein e2 allele. The frequency distribution of apoE phenotypes is given in Table 2 . The frequency of patients with at least one e2 allele (E2/3 + E4/ 2) was 15 % (n = 92). Patients with the e2 allele had a significantly lower systolic blood pressure (p = 0.04), higher smoking rates (p = 0.03) and lower LDL-cholesterol concentrations (p = 0.0006) than those without the e2 allele. Even after adjustment for age and sex, the LDL-cholesterol concentration was significantly lower in patients with an e2 allele than in patients without (p = 0.0003) (data not shown). Albuminuria was present in 34 % of the patients with an e2 allele (n = 92) compared with 29 % of the patients without an e2 allele (p for trend = 0.4). In a logistic regression model (Table 3) there was no association between e2 allele and either albuminuria at baseline or progression of albuminuria, with or without adjustment for lipids. Further adjustment for systolic blood pressure did not alter this relation (data not shown).
Discussion
The main findings in this study are that patients with albuminuria have a significantly lower HDL-cholesterol:apoA-I + apoA-II ratio at baseline. This altered composition could contribute to the increased risk of coronary artery disease in these patients. The relation between HDL-cholesterol:apoA-I + apoA-II ratio Baseline: microalbuminuria and macroalbuminuria vs normoalbuminuria.
Progression: early progressors vs non-progressors. c = cholesterol a log transformed and albuminuria is not independent of LDL-cholesterol or fasting triglyceride. There is only a weak non-statistically significant association between HDL-cholesterol:apoA-I + apoA-II ratio and progression of albuminuria and no association between the e2 allele and albuminuria. There are only two cross-sectional studies which have analysed the HDL-cholesterol:apoA-I + apoA-II ratio in patients with Type I diabetes [11, 32] . In one of these studies, the HDL-cholesterol:apoA-I + apoA-II ratio was used as a measurement of the composition of HDL but this ratio was not analysed in relation to nephropathy [32] . In the other study, a significantly lower HDL-cholesterol:apoA-I + apoA-II ratio was found in microalbuminuric or macroalbuminuric patients compared with normoalbuminuric patients [11] . Whether this relation was independent of LDL-cholesterol or fasting triglyceride was not examined. After adjustment for LDL-cholesterol or fasting triglyceride in our study there was no longer a statistically significant relation between HDL-cholesterol:apoA-I + apoA-II ratio and albuminuria at baseline. These data are consistent with increasing triglyceride associated with nephropathy being the main determinant of the altered HDL composition possibly resulting from an accelerated exchange of cholesterol for triglyceride from HDL-cholesterol to triglyceride-rich lipoproteins [33, 34, 35] . We did not find any clear evidence that HDL compositional abnormalities are a risk factor for the initiation and progression of albuminuria although there was a weak non-statistically significant association. The number of early progressors was, however, very small, thereby reducing the power of our analysis (n = 34).
Studies of the absolute concentrations of apoA-I and apoA-II in patients with Type I diabetes and microalbuminuria have been inconsistent, finding reduced [8, 36] , unchanged [4, 6, 11] and increased [37, 38] concentrations of apolipoproteins in microalbuminuric patients compared with normoalbuminuric patients. In our larger study, we found similar apoA-I concentrations and increased apoA-II concentrations in microalbuminuric patients compared with normoalbuminuric patients.
The absence of an association between the e2 allele and nephropathy found here is consistent with a previous study of 146 Type I diabetic patients [18] . Two previous studies (n = 162 and 252) did, however, find an association [17, 19] . Two out of three studies in patients with Type II (non-insulin-dependent) diabetes mellitus found that the e2 allele was associated with increased risk of nephropathy [31, 39, 40] . One reason for these conflicting results is that previous studies had smaller numbers of diabetic patients with an e2 allele than our study [17, 18, 19, 31, 39, 40] . Another possibility is that the relation between the e2 allele and nephropathy is mediated through triglyceride. In patient groups where the e2 allele is a less important determinant of triglyceride concentrations, the association between the e2 allele and nephropathy could be weaker. We did not find a relation between the e2 allele and fasting triglyceride in our patients. The other three studies of e2 allele and nephropathy in Type I diabetes did not examine the relation between the e2 allele and triglyceride concentration [17, 18, 19] . Most previous studies in Type II diabetes, that found that the e2 allele is associated with the development of diabetic nephropathy also found an increased concentration of triglyceride in patients with any e2 allele compared with those without [31, 39] but they did not adjust for triglyceride.
We conclude that there is no relation between the e2 allele and albuminuria. Our data emphasise the necessity of showing the replicability of results in genotype-phenotype association studies.
Patients with albuminuria, along with increased triglyceride and LDL-cholesterol concentrations have compositional abnormalities in HDL emphasising the need for vigilant lipid lowering therapy in this patient group. The altered HDL composition associated with albuminuria could be important in the increased risk of cardiovascular disease in these patients.
